Impel NeuroPharma, Inc. (IMPL)
|Net Income (ttm)||-46.32M|
Impel NeuroPharma has filed to raise $75 million in an IPO to bring a migraine drug to market. The candidate, Trudhesa, is delivered using a metered dose device intended to get the active ingredient int...
Impel NeuroPharma, Inc. has filed to go public with an IPO on the NASDAQ.
Veeva (VEEV) collaborates with Impel to accelerate the pre-launch planning and digital-first commercial execution for migraine treatment.
Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing our proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system, or CNS. We have designed our proprietary Precision Olfactory Delivery, or POD, upper nasal delivery technology to target the vascular-rich upper nasal cavity, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, pro... [Read more...]
|IPO Date |
Apr 23, 2021
|Stock Exchange |
|Ticker Symbol |